By Ana Espino | Published on April 17, 2026 | 4 min read
Hemophilia is a rare genetic disorder characterized by a
deficiency in coagulation factor VIII (hemophilia A) or IX (hemophilia B). This
condition leads to recurrent bleeding episodes that can result in severe
complications such as joint damage, chronic pain, and, in some cases,
life-threatening hemorrhages. Beyond its clinical impact, hemophilia
significantly affects the quality of life of patients and their families.
Despite therapeutic advances, current treatments have major
limitations. Replacement therapies require lifelong regular injections, which
are often burdensome and costly. In addition, the development of neutralizing
antibodies against administered factors reduces their effectiveness.
Non-replacement therapies, although innovative, do not completely eliminate the
risk of bleeding, particularly in cases of trauma.
In this context, several challenges remain: improving
treatment durability, reducing therapeutic burden, limiting immune responses,
and expanding access to patients, particularly pediatric populations.
Against this backdrop, gene therapy appears to be a
promising strategy. The aim of this review is to analyze the main approaches
under development—AAV vectors, lentiviral vectors, and genome editing—in order
to assess their potential, limitations, and future perspectives.
Does gene therapy really work ?
This study is based on a comprehensive review of available
preclinical and clinical data on the different gene therapy strategies for
hemophilia. It examines mechanisms of action, clinical trial outcomes, as well
as the advantages and limitations of each approach.
AAV-based gene therapies are currently the most advanced
clinically. They have demonstrated a significant increase in coagulation factor
levels, accompanied by a marked reduction in bleeding episodes and reliance on
conventional treatments. However, these approaches are limited by immune
responses, particularly hepatic ones, sometimes requiring prolonged
immunosuppression. In addition, their efficacy may be compromised in patients
with pre-existing antibodies, and durability remains variable, especially in hemophilia
A.
Lentiviral approaches offer a major advantage: integration
of the therapeutic gene into the genome, allowing potentially long-term
expression, including in dividing cells. This opens interesting prospects,
particularly for pediatric patients. However, these strategies are still at an
early stage and carry risks, notably related to conditioning regimens and
insertional mutagenesis, which may lead to serious adverse effects.
Finally, genome editing techniques such as CRISPR-Cas9
represent an innovative approach aimed at directly correcting the genetic
defect underlying the disease. They offer curative potential with high
precision. Nevertheless, these technologies are still in early development and
raise concerns regarding off-target effects and delivery challenges.
Overall, these approaches show encouraging results, with
improved disease control, but still require optimization to ensure long-term
safety and efficacy.
How far can these new approaches go ?
Hemophilia, as a chronic genetic disease, remains associated
with a significant therapeutic burden and substantial complications. Current
challenges mainly concern treatment durability, management of immune responses,
and access to these new therapies for all patients, especially children.
This study aimed to evaluate advances in different gene
therapy approaches, highlighting their benefits and limitations. The results
confirm that gene therapy represents a major breakthrough, with the potential
to transform hemophilia management by offering single-administration treatments
with long-lasting—or even curative—effects.
However, some limitations persist, including limited
long-term data, uncertainties regarding the durability of coagulation factor
expression, and constraints related to patient eligibility. Nevertheless, the
outlook is promising. Future research should improve the safety and efficacy of
these approaches, overcome immunological barriers, and extend these innovations
to broader patient populations. Genome editing, in particular, could ultimately
provide a durable curative solution for all patients with hemophilia.
Read next: Fitusiran: what if we rebalanced coagulation?
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap
between research and real-world impact. With expertise in immunology, virology,
oncology, and clinical studies, she makes complex science clear and accessible.
Her mission: to accelerate knowledge sharing and empower evidence-based
decisions through impactful communication.
